Analysts Expect Diplomat Pharmacy Inc (DPLO) to Post $0.23 Earnings Per Share

Analysts expect that Diplomat Pharmacy Inc (NYSE:DPLO) will announce earnings per share of $0.23 for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Diplomat Pharmacy’s earnings, with the highest EPS estimate coming in at $0.24 and the lowest estimate coming in at $0.21. Diplomat Pharmacy posted earnings per share of $0.25 during the same quarter last year, which would suggest a negative year over year growth rate of 8%. The firm is scheduled to report its next quarterly earnings report on Monday, August 6th.

On average, analysts expect that Diplomat Pharmacy will report full year earnings of $0.92 per share for the current financial year, with EPS estimates ranging from $0.90 to $0.95. For the next fiscal year, analysts expect that the company will report earnings of $1.12 per share, with EPS estimates ranging from $1.01 to $1.22. Zacks’ earnings per share calculations are an average based on a survey of research firms that follow Diplomat Pharmacy.

Diplomat Pharmacy (NYSE:DPLO) last announced its quarterly earnings data on Monday, May 7th. The company reported $0.20 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.21 by ($0.01). Diplomat Pharmacy had a net margin of 0.23% and a return on equity of 8.80%. The company had revenue of $1.34 billion for the quarter, compared to analysts’ expectations of $1.28 billion. During the same period in the prior year, the firm earned $0.19 earnings per share. The firm’s quarterly revenue was up 24.4% on a year-over-year basis.

Several brokerages have recently issued reports on DPLO. Morgan Stanley boosted their price objective on shares of Diplomat Pharmacy from $16.00 to $21.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 3rd. ValuEngine cut shares of Diplomat Pharmacy from a “buy” rating to a “hold” rating in a research note on Monday, July 2nd. JPMorgan Chase & Co. raised shares of Diplomat Pharmacy from a “neutral” rating to an “overweight” rating in a research note on Thursday, May 10th. Zacks Investment Research cut shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research note on Tuesday, May 1st. Finally, Leerink Swann reissued an “outperform” rating and set a $33.00 price objective on shares of Diplomat Pharmacy in a research note on Friday, June 22nd. Eight research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $26.64.

Shares of Diplomat Pharmacy traded down $0.63, hitting $26.14, during trading on Friday, according to MarketBeat. 727,165 shares of the company traded hands, compared to its average volume of 897,043. Diplomat Pharmacy has a 1 year low of $14.50 and a 1 year high of $28.74. The stock has a market capitalization of $2.01 billion, a PE ratio of 31.55 and a beta of 1.33. The company has a quick ratio of 0.57, a current ratio of 0.88 and a debt-to-equity ratio of 0.59.

In other news, Director Jeffrey G. Park sold 1,695 shares of the company’s stock in a transaction dated Monday, June 11th. The shares were sold at an average price of $25.26, for a total value of $42,815.70. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Shawn Tomasello sold 1,680 shares of the company’s stock in a transaction dated Tuesday, June 5th. The shares were sold at an average price of $24.27, for a total transaction of $40,773.60. Following the completion of the sale, the director now owns 12,816 shares in the company, valued at approximately $311,044.32. The disclosure for this sale can be found here. Over the last three months, insiders sold 17,250 shares of company stock valued at $419,364. 24.70% of the stock is currently owned by corporate insiders.

Several institutional investors have recently modified their holdings of the company. BlackRock Inc. raised its stake in shares of Diplomat Pharmacy by 3.6% in the 4th quarter. BlackRock Inc. now owns 6,754,710 shares of the company’s stock valued at $135,566,000 after purchasing an additional 237,500 shares in the last quarter. Frontier Capital Management Co. LLC raised its stake in shares of Diplomat Pharmacy by 2.5% in the 1st quarter. Frontier Capital Management Co. LLC now owns 3,919,051 shares of the company’s stock valued at $78,969,000 after purchasing an additional 94,861 shares in the last quarter. GW&K Investment Management LLC raised its stake in shares of Diplomat Pharmacy by 1.9% in the 1st quarter. GW&K Investment Management LLC now owns 1,024,336 shares of the company’s stock valued at $20,640,000 after purchasing an additional 19,222 shares in the last quarter. Point72 Asset Management L.P. raised its stake in shares of Diplomat Pharmacy by 1,424.3% in the 1st quarter. Point72 Asset Management L.P. now owns 939,562 shares of the company’s stock valued at $18,932,000 after purchasing an additional 877,922 shares in the last quarter. Finally, Redwood Investments LLC acquired a new stake in shares of Diplomat Pharmacy in the 1st quarter valued at about $16,716,000. Institutional investors and hedge funds own 75.66% of the company’s stock.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Get a free copy of the Zacks research report on Diplomat Pharmacy (DPLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply